Novo Nordisk markets Norditropin Simplexx, a branded injectable growth hormone.
Julia Harries, recently promoted from a director to deputy managing director role at Red Door, described effects on quality of life and emotional impacts of growth disorders as 'severe'.
Around 4,500 children in the UK receive treatment for growth disorders, but identification is often patchy. It has been estimated that more than 40 per cent of all children who could benefit from hormone treatment do not currently receive it.
There is also political disagreement over how often children should be measured for abnormalities.